{{Rsnum
|rsid=2486001
|Gene=SLC6A9
|Chromosome=1
|position=44010315
|Orientation=minus
|GMAF=0.1524
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC6A9
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 2.7 | 19.5 | 77.9
| HCB | 3.7 | 30.1 | 66.2
| JPT | 4.4 | 41.6 | 54.0
| YRI | 0.0 | 7.5 | 92.5
| ASW | 0.0 | 19.3 | 80.7
| CHB | 3.7 | 30.1 | 66.2
| CHD | 1.8 | 36.7 | 61.5
| GIH | 5.0 | 28.7 | 66.3
| LWK | 0.0 | 19.1 | 80.9
| MEX | 5.2 | 29.3 | 65.5
| MKK | 0.0 | 21.8 | 78.2
| TSI | 6.9 | 24.8 | 68.3
| HapMapRevision=28
}}

{{PMID|17582620}} significant association with [[methamphetamine dependence]] among a sample of 204 assumedly Japanese patients with methamphetamine-use disorder and 210 controls. a haplotype consisting of [[rs2486001]](T)-[[rs2248829]](C) was noted as being a significant risk factor (OR = 2.04, p = 0.000039)

{{PMID Auto
|PMID=19556729
|Title=Association of SLC6A9 Gene Variants with Human Essential Hypertension
}}

{{on chip | Illumina Human 1M}}